Search for tag: "sp142"

Case Study: Assessing PD-L1 in TNBC - Select cases with staining near the scoring algorithm cut-off

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the borderline tissue staining of IC around 1% of tumor area that a pathologist will see in the…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 3 plays

Case Study: Assessing PD-L1 in TNBC - Scoring cases with common staining patterns

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the most common pattern of tissue staining a pathologist will see in the triple negative breast…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 2 plays

Case Study: Assessing PD-L1 in TNBC. Moderate IC staining without TC staining

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the most common tissue staining pattern a pathologist will see in the triple negative breast cancer…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 2 plays

PD-L1 testing and SP142 assay as a diagnostic tool in triple negative breast cancer (TNBC)

VENTANA PD-L1 (SP142) assay is the first and only FDA-approved assay for mTNBC*. Testing for PD-L1 identifies patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC** This video is…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 3 plays

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1 (SP142) IHC assay is FDA-approved for mTNBC. Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC* This video is intended for US healthcare…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 5 plays

PD-L1 Testing and SP142 IHC Assay as a Diagnostic Tool in Urothelial Carcinoma

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. SP142 assay is optimized for staining for both immune and…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 6 plays

PD-L1 Testing and Developmental Process for Companion Diagnostic Tests

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses on: 1. The PD-L1 biomarker and its role in immunotherapy - time…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 9 plays

PD-L1 Expression on Immune and Tumor Cells

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. How and why PD-L1 is present on tumor cells as well as being…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 10 plays

Tumor Microenvironment and PD-L1 biomarker

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses the tumor microenvironment, the cancer immunity cycle, the immune…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 3 plays

Down the Ocular Episode # 3 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 2

This episode is part 2 in a series on the PD-L1 (SP142) assay in non small cell lung cancer. In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 1 plays

Down the Ocular Episode # 2 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 1

In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD and Tabari Baker, PhD discuss the PD-L1 (SP142) assay in non-small cell lung cancer. Drs.…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 4 plays

Changing Landscape of PD-L1-high NSCLC treatments

Changing landscape for PD-L1-high NSCLC treatmentsSpeakers: Dr Ross Soo (Singapore, Moderator), Dr Mark Socinski (US, Speaker), Dr Roy Herbst (US, Speaker), Dr Yuh Min Chen (Taiwan,…

From  Kelda Tan on November 2nd, 2020 0 likes 137 plays 0